Acknowledgement
This work was supported by the Zhejiang Provincial Natural Science Foundation of China (Grant number: LQ22H160014) and the National Natural Science Foundation of China (Grant number: 82102816).
References
- Siegel RL, Giaquinto AN and Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74, 12-49
- Herbst RS, Morgensztern D and Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553, 446-454
- Lahiri A, Maji A, Potdar PD et al (2023) Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer 22, 40
- Beaty BT and Weiner AA (2020) Alternatives to surgery for early-stage non-small cell lung cancer: stereotactic radiotherapy. Clin Chest Med 41, 185-195
- Tini P, Nardone V, Pastina P, Pirtoli L, Correale P and Giordano A (2018) The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer. Expert Rev Anticancer Ther 18, 593-602
- Yu J, Zhang W, Lu B et al (2018) miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M. Oncol Lett 15, 3305-3312
- Khanal P, Yun HJ, Lim SC et al (2012) Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells. Oncogene 31, 3845-3856
- Zhang X, Zhao Y, Yiminniyaze R et al (2023) CDK10 suppresses metastasis of lung adenocarcinoma through inhibition of the ETS2/c-Raf/p-MEK/p-ERK signaling loop. Mol Carcinog 63, 61-74
- Li H, You Y and Liu J (2018) Cyclin‑dependent kinase 10 prevents glioma metastasis via modulation of Snail expression. Mol Med Rep 18, 1165-1170
- You Y, Yang W, Wang Z et al (2013) Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas. Cell Oncol (Dordr) 36, 323-331
- Zhong XY, Xu XX, Yu JH et al (2012) Clinical and biological significance of Cdk10 in hepatocellular carcinoma. Gene 498, 68-74
- Zhao BW, Chen S, Li YF et al (2017) Low expression of CDK10 correlates with adverse prognosis in gastric carcinoma. J Cancer 8, 2907-2914
- You Y, Li H, Qin X et al (2015) Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report. Cell Oncol (Dordr) 38, 485-491
- Yu JH, Zhong XY, Zhang WG et al (2012) CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. Oncol Rep 27, 1266-1276
- Iorns E, Turner NC, Elliott R et al (2008) Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13, 91-104
- Weiswald LB, Hasan MR, Wong JCT et al (2017) Inactivation of the kinase domain of CDK10 prevents tumor growth in a preclinical model of colorectal cancer, and is accompanied by downregulation of Bcl-2. Mol Cancer Ther 16, 2292-2303
- Kumar A, Singh UK, Kini SG et al (2015) JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases. Future Med Chem 7, 2065-2086
- Zhang D, Jiang Q, Ge X et al (2021) RHOV promotes lung adenocarcinoma cell growth and metastasis through JNK/c-Jun pathway. Int J Biol Sci 17, 2622-2632
- Jiao CY, Feng QC, Li CX et al (2021) BUB1B promotes extrahepatic cholangiocarcinoma progression via JNK/c-Jun pathways. Cell Death Dis 12, 63
- Liu Y, Sui A, Sun J, Wu Y, Liu F and Yang Y (2023) c-Jun-mediated JMJD6 restoration enhances resistance of liver cancer to radiotherapy through the IL-4-activated ERK pathway. Cell Biol Int 47, 1392-1405
- Sun Y, Chen K, Lin G, Wan F, Chen L and Zhu X (2021) Silencing c-Jun inhibits autophagy and abrogates radioresistance in nasopharyngeal carcinoma by activating the PI3K/AKT/mTOR pathway. Ann Transl Med 9, 1085
- Barker HE, Paget JT, Khan AA and Harrington KJ (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15, 409-425
- Vinod SK and Hau E (2020) Radiotherapy treatment for lung cancer: current status and future directions. Respirology 25 Suppl 2, 61-71
- Olivares-Urbano MA, Grinan-Lison C, Marchal JA and Nunez MI (2020) CSC radioresistance: a therapeutic challenge to improve radiotherapy effectiveness in cancer. Cells 9, 1651
- Bazzi ZA and Tai IT (2021) CDK10 in gastrointestinal cancers: dual roles as a tumor suppressor and oncogene. Front Oncol 11, 655479
- You Y, Bai F, Ye Z et al (2018) Downregulated CDK10 expression in gastric cancer: association with tumor progression and poor prognosis. Mol Med Rep 17, 6812-6818
- Huang RX and Zhou PK (2020) DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther 5, 60
- Vasireddy RS, Sprung CN, Cempaka NL, Chao M and McKay MJ (2010) H2AX phosphorylation screen of cells from radiosensitive cancer patients reveals a novel DNA double-strand break repair cellular phenotype. Br J Cancer 102, 1511-1518
- Wang Y, Wang J, Zhao A, Huang X and Zhang X (2022) HPV16 E6E7 up-regulates KIF2A expression by activating JNK/c-Jun signal, is beneficial to migration and invasion of cervical cancer cells. Open Med (Wars) 17, 1780-1787
- Qiao GB, Wang RT, Wang SN, Tao SL, Tan QY and Jin H (2021) GRP75-mediated upregulation of HMGA1 stimulates stage I lung adenocarcinoma progression by activating JNK/c-JUN signaling. Thorac Cancer 12, 1558-1569
- Budwit-Novotny DA, McCarty KS, Cox EB et al (1986) Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46, 5419-5425